US FDA updates cardiotoxicity warning for mitoxantrone
This article was originally published in Scrip
Executive Summary
The US FDAhas alerted US doctors who treat patients with the multiple sclerosis product, mitoxantrone (marketed as Serono’s Novantrone and generics), of the importance of evaluating left ventricular ejection fraction before initiating treatment and prior to administration of every dose of the product.